Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myasthenia gravis.

Michael W Nicolle1

  • 1Department of Clinical Neurological Sciences, London Health Sciences Center, The University of Western Ontario, London, Ontario, Canada. mnicolle@uwo.ca

The Neurologist
|June 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Review: Mental Health Outcomes in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2025
Same author

Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.

European journal of neurology·2025
Same author

Testing for Acetylcholine Receptor and Muscle-Specific Tyrosine Kinase Antibodies by Fixed Cell-Based Assay in Clinical Practice: Positive Predictive Value for Myasthenia Gravis.

European journal of neurology·2025
Same author

Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial.

Muscle & nerve·2024
Same author

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.

Neurology·2022
Same author

A Young Man With Acute-Onset Bilateral Arm Weakness After Traumatic Sciatic Neuropathy: A Clinical Vignette.

American journal of physical medicine & rehabilitation·2022
Same journal

Looking Beyond the Midline: An Uncommon Etiology of Internuclear Ophthalmoplegia of Abduction Due to Cerebral Venous Thrombosis.

The neurologist·2026
Same journal

Commentary: Cervical Artery Dissection and Chiropractic Cervical Manipulation: Clarifying Association, Mechanism, and Interpretation.

The neurologist·2026
Same journal

Acute Spinal Cord Infarct Secondary to Fibrocartilaginous Embolism Treated With Tenecteplase.

The neurologist·2026
Same journal

Cervical Artery Dissection and Chiropractic​​​​​.

The neurologist·2026
Same journal

Oromandibular Dyskinesia Associated With Levofloxacin and Responsive to Low-Dose Oral Diazepam: A Case Report.

The neurologist·2026
Same journal

Spinal H-Sign in Syphilitic Myelitis Mimicking MOGAD.

The neurologist·2026
See all related articles

Myasthenia gravis (MG) treatments have improved, targeting neuromuscular transmission or immune responses. However, challenges remain with treatment efficacy and adverse effects for many MG patients.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Myasthenia gravis (MG) is a prototype autoimmune disorder affecting neuromuscular transmission.
  • Antibodies against acetylcholine receptors cause muscle weakness in MG.
  • Effective treatments for MG have emerged in the last three decades.

Purpose of the Study:

  • To review normal neuromuscular transmission.
  • To outline MG clinical features and diagnostic tests.
  • To discuss current MG treatments, their mechanisms, and adverse effects.

Main Methods:

  • Literature review of MG diagnosis and treatment.
  • Analysis of evidence-based treatment options.
  • Identification of areas of controversy in MG management.

Related Experiment Videos

Main Results:

  • Significant advancements in MG diagnosis and management.
  • Treatments improve neuromuscular transmission or modulate the immune response.
  • Treatment strategies are individualized based on disease severity and patient factors.

Conclusions:

  • Modern MG treatments offer an optimistic outlook but face challenges.
  • Lack of efficacy and significant adverse effects persist for some patients.
  • Detailed knowledge of treatment mechanisms and side effects is crucial for individualized care.